Trial Information

Prospective, Randomized Study of PIVKA-II and AFP Measurement Every 3 Months Compared to AFP Every 6 Months in Surveillance Program for Early Detection of Hepatocellular Carcinoma

There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the
role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance
program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to
compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in
diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used